

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES


Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



Atty.
Dkt. No.

M#

Client Ref.

037003-0280609

2000-30-0154A

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Applicant: Grillo-Lopez

Appln. No.: 09/840,872

Filing Date: April 25, 2001

Examiner: Gary B. Nickol

Group Art Unit: 1642

Date: September 25, 2003

Page

1

6

RECEIVED
OCT 01 2003
TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

Examiner's Initials*		Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
GN	AR	4,348,376	09/1982	Goldenberg	424	1	
	BR	4,454,106	06/1984	Gansow, et al.	424	1.1	
	CR	4,460,559	07/1984	Goldenberg	424	1.1	
	DR	4,472,509	09/1984	Gansow, et al.	436	548	
	ER	4,665,077	05/1987	Stringfellow, et al.	514	269	
	FR	4,816,567	03/1989	Cabilly, et al.	530	387	
	GR	4,831,175	05/1989	Gansow, et al.	558	17	
	HR	5,114,721	05/1992	Cohen, et al.	424	534	
	IR	5,116,964	05/1992	Capon, et al.	536	27	
	JR	5,182,107	01/1993	Friden	424	85.91	
	KR	5,500,362	03/1996	Robinson, et al.	435	7.23	
	LR	5,595,721	01/1997	Kaminski, et al.	424	1.49	
	MR	5,674,492	10/1997	Armitage, et al.	424	144.1	
	NR	5,677,180	10/1997	Robinson, et al.	435	328	
	OR	5,693,780	12/1997	Newman, et al.	536	23.53	
	PR	5,736,137	04/1998	Anderson, et al.	424	133.1	
	QR	5,747,037	05/1998	Noelle, et al.	424	154.1	
	RR	5,776,456	07/1998	Anderson, et al.	424	133.1	
	SR	5,801,227	09/1998	Fanslow, III et al.	530	388.73	
	TR	5,821,337	10/1998	Carter, et al.	530	387.3	
	UR	5,833,987	11/1998	Noelle, et al.	424	154.1	
	VR	5,843,398	12/1998	Kaminski, et al.	424	1.49	
	WR	5,843,439	12/1998	Anderson, et al.	424	133.1	
	XR	5,874,082	02/1999	de Boer	424	153.1	
	YR	5,874,085	02/1999	Mond, et al.	424	195.11	
	ZR	5,876,718	03/1999	Noelle, et al.	424	154.1	
	AAR	5,716,614	02/1998	Katz, et al.	424	94.3	
	BBR	6,001,358	12/1999	Black, et al.	424	154.1	
	CCR	6,183,744	02/2001	Goldenberg	424	131.1	
	DDR	6,306,393	10/2001	Goldenberg	424	141.1	

FOREIGN PATENT DOCUMENTS

		Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract		Translation Readily Available	
						Enclosed	No	Enclose	No
GN	EER	0 340 109 B1	05/1997	EP	Steinman, et al.				
	FFR	0 404,097 B1	09/1996	EP	Bosslet, et al.				
	GGR	0 555 880 A2	08/1993	EP	Aruffo, et al.				
	HHR	0 555 880 A3	08/1993	EP	Aruffo, et al.				

GN	IIR	WO 90/081	07/1990	WO	Reinherz, et al.				
	JJR	WO 90/11294	10/1990	WO	Howell, et al.				
	KKR	WO 91/01133	02/1991	WO	Goldstein, et al.				
	LLR	WO 93/11161	06/1993	WO	Whitlow, et al.				
SEP 26 2003	MMR	WO 94/11026	05/1994	WO	Anderson, et al.				
	NNR	WO 95/06666	03/1995	WO	Noelle, et al.				
	OOOR	WO 95/17202	06/1995	WO	Armitage, et al.				

RECEIVE

OCT 01 2003

TECH CENTER 1600/2900

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)



GN	PPR	Abrey <i>et al.</i> , Combination chemotherapy in primary central nervous system lymphoma," (abstract) <u>Proc. Am. Soc. Clin. Onc.</u> (1999)							
	QQR	Abrey <i>et al.</i> , Long-term survival in primary CNS lymphoma, <u>J. Clin. Oncol.</u> 16: 859-63 (1998)							
	RRR	Armitage <i>et al.</i> , Molecular and biological characterization of a murine ligand for CD40, <u>Nature</u> 357:80-82 (1992)							
	SSR	Behr <i>et al.</i> , Low-versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies, <u>Clin. Cancer Res.</u> 5: 3304s-14s (1999)							
	TTR	Bejcek <i>et al.</i> , Development and characterization of three recombinant single chain antibody fragments (scFvs) directed against the CD19 antigen, <u>Cancer Res.</u> 55: 2346-51 (1995)							
	UUR	Benoit <i>et al.</i> , Increased inhibition of proliferation of human B cell lymphomas following ligation of CD40, and either CD19, CD20, CD95 or surface immunoglobulin, <u>Immunopharmacology</u> 35: 129-139 (1996)							
	VVR	Berinstein <i>et al.</i> , Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma, <u>Ann. Oncol.</u> 9: 995-1001 (1998)							
	WWR	Blay <i>et al.</i> , High-dose methotrexate for the treatment of primary cerebral lymphomas: Analysis of survival and late neurologic toxicity in a retrospective series, <u>J. Clin. Oncol.</u> 16: 864-871 (1998)							
	XXR	Bolognesi <i>et al.</i> , Evaluation of immunotoxins containing single-chain ribosome-inactivating proteins and an anti-CD22 monoclonal antibody (OM124): <i>in vitro</i> and <i>in vivo</i> studies, <u>Br. J. Haematol.</u> 101: 179-88 (1998)							
	YYR	Capon <i>et al.</i> , Designing CD4 immunoadhesins for AIDS therapy, <u>Nature</u> 337: 525-531 (1989)							
	ZZR	Chamberlain <i>et al.</i> , Primary central nervous system lymphoma: a role for adjuvant chemotherapy, <u>J. Neuro. Oncol.</u> 14: 271-275 (1992)							
	AAAR	Cheng <i>et al.</i> , Systemic chemotherapy alone for patients with non-acquired immunodeficiency syndrome-related central nervous system lymphoma, <u>Cancer</u> 82: 1946-51 (1998)							
	BBBR	Clodi <i>et al.</i> , Unbalanced expression of Fas and CD40 in mantle cell lymphoma, <u>Brit. J. Haematol.</u> 103: 217-9 (1998)							
	CCCR	Clynes <i>et al.</i> , Fc receptors are required in passive and active immunity to melanoma, <u>PNAS (USA)</u> 95:652-656 (1998)							
	DDDR	Coiffier <i>et al.</i> , Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study, <u>Blood</u> 92: 1927-1932 (1998)							
	EEER	Czuczman <i>et al.</i> , Treatment of patients with low-grade B-cell lymphoma with the combinations of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy, <u>J. Clin. Oncol.</u> 17: 268-76 (1999)							
	FFFR	DeAngelis <i>et al.</i> , "Primary Central Nervous System Lymphoma," IN <u>CANCER: PRINCIPLES & PRACTICE OF ONCOLOGY</u> 2233-2242 (DeVita <i>et al.</i> , eds. 1997).							
	GGGR	Deguchi <i>et al.</i> , Retention of biologic activity of human epidermal growth factor following conjugation of a blood-brain barrier drug delivery vector via an extended poly(ethylene glycol) linker, <u>Bioconjug. Chem.</u> 10: 32-37 (1999)							
	HHHR	Endo, <u>Gan To Kagaku Ryoho</u> 26: 744-748 (1999)							

IIIR	Finé <i>et al.</i> , Primary central nervous system lymphoma, <u>Ann. Intern. Med.</u> 119: 1093-1104 (1993)				
IIJR	Flavell <i>et al.</i> , Therapy of human B-cell lymphoma bearing SCID mice is more effective with anti-CD19- and anti-CD38-saporin immunotoxins used in combination than with either immunotoxin used alone, <u>Int. J. Cancer</u> 62: 337-44 (1995)				
KKRR	Freilich <i>et al.</i> , Chemotherapy without radiation therapy as initial. Treatment for primary CNS lymphoma in older patients, <u>Neurology</u> 46: 435-439 (1996)				
LLLR	Funakoshi <i>et al.</i> , Inhibition of human B-cell lymphoma growth by CD40 stimulation, <u>Blood</u> 83: 2787-2794 (1994)				
MMMR	Funakoshi <i>et al.</i> , Differential in vitro and in vivo antitumor effects mediated by anti-CD40 and anti-CD20 monoclonal antibodies against human B-cell lymphomas, <u>J. Immunother. Emphasis Tumor Immunol.</u> 19: 93-101 (1996)				
NNNR	Ghetie <i>et al.</i> , Anti-CD19 antibodies inhibit the function of the P-gp pump in multidrug-resistant B lymphoma cells, <u>Clin. Cancer Res.</u> 5: 3920-7 (1999)				
OOOR	Green <i>et al.</i> , Evidence for a continued requirement for CD40/CD40 ligand (CD154) interactions in the progression of LP-BM5 retrovirus-induced murine AIDS, <u>Virology</u> 241: 260-268 (1998)				
PPPR	Gruss <i>et al.</i> , CD40/CD40 ligand interactions in normal, reactive and malignant lympho-hematopoietic tissues, <u>Leuk. Lymphoma</u> 24: 393-422 (1997)				
QQQR	Hekman <i>et al.</i> , Initial experience with treatment of human B cell lymphoma with anti-CD19 monoclonal antibody <u>Cancer Immunol. Immunother.</u> 32:364-372 (1991)				
RRRR	Herrlinger <i>et al.</i> , Intrathecal therapy of leptomeningeal CEM T-cell lymphoma in nude rats with anti-CD7 ricin toxin A chain immunotoxin, <u>J. Neurooncol.</u> 40: 1-9 (1998)				
SSSR	Hollenbaugh <i>et al.</i> , The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co-stimulatory activity, <u>EMBO J.</u> 11:4313-4321 (1992)				
TTTR	Hollinger <i>et al.</i> , "Diabodies": small bivalent and bispecific antibody fragments, <u>Proc. Natl. Acad. Sci. USA</u> , 90:6444-6448 (1993).				
UUUR	Huwylar <i>et al.</i> , Brain drug delivery of small molecules using immunoliposomes, <u>Proc. Nat'l Acad. Sci. USA</u> 93: 14164-14169 (1996)				
VVVR	Illidge <i>et al.</i> , The importance of antibody-specificity in determining successful radioimmunotherapy of B-cell lymphoma, <u>Blood</u> 94: 233-43 (1999)				
WWWR	Janeway, Immunotherapy by peptides, <u>Nature</u> , 341: 482 (1989)				
XXXR	Johnson <i>et al.</i> , Isolated follicular lymphoma cells are resistant to apoptosis and can be grown in vitro in the CD40/stromal cell system, <u>Blood</u> 82: 1848-1857 (1993)				
YYR	Kiesel <i>et al.</i> , Removal of cells from a malignant B-cell line from bone marrow with immunomagnetic beads and with complement and immunoglobulin switch variant mediated cytolysis, <u>Leukemia Research</u> 11, 12: 1119 (1987)				
ZZZR	Kramer <i>et al.</i> , Tc-99m LL-2 Fab' monoclonal antibody imaging in acquired immune deficiency syndrome-related lymphoma, <u>Cancer</u> 80: 2469-2477 (1997)				
AAAAR	Kroll <i>et al.</i> , Outwitting the blood-brain barrier for therapeutic purposes: Osmotic opening and other means, <u>Neurosurgery</u> 42: 1083-99 (1998)				
BBBBR	Ledbetter <i>et al.</i> , Agonistic and antagonistic properties of CD40 mAb G28-5 are dependent on binding valency, <u>Circ. Shock</u> 44: 67-72 (1994)				

RECEIVED

OCT 01 2003

TECH CENTER 1600/2900

	CCCCR	Lederman <i>et al.</i> , Identification of a novel surface protein on activated CD4+ T cells that induces contact-dependent B cell differentiation (Help), <u>J. Exp. Med.</u> 175: 1091-1101 (1992)			
	JDDDR	Leget <i>et al.</i> , Use of rituximab, the new FDA-approved antibody, <u>Curr. Opin. Oncol.</u> 10: 548-551 (1998)			
	EEER	Lesser <i>et al.</i> , The chemotherapy of adult primary brain tumor, <u>Cancer Treat. Rev.</u> 19: 261-281 (1993)			
	FFFFR	Li <i>et al.</i> , Pharmacokinetics and biodistribution of radioimmunoconjugates of anti-CD19 antibody and single-chain Fv for treatment of human B-cell malignancy, <u>Cancer Immunol. Immunother.</u> 47: 121-30 (1998)			
	GGGGR	Lieberman <i>et al.</i> , Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion, <u>J. Neurosurg.</u> 82: 1021-1029 (1995)			
	HHHHR	Linsley <i>et al.</i> , Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation, <u>J. Exp. Med.</u> 178: 721-730 (1991)			
	IIIR	Maloney <i>et al.</i> , IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma, <u>Blood</u> 90: 2188-2195 (1997)			
	JJJJR	Mansfield <i>et al.</i> , Characterization of RFB4-pseudomonas exotoxin A immunotoxins targeted to CD22 on B-cell malignancies, <u>Bioconjug. Chem.</u> 7: 557-63 (1996)			
	KKKKR	Mason <i>et al.</i> , ¹¹¹ Indium-diethylenetriamine pentaacetic acid cerebrospinal fluid flow studies predict distribution of intrathecally administered chemotherapy and outcome in patients with leptomeningeal metastases, <u>Neurology</u> 50: 438-444 (1998)			
	LLLLR	McLaughlin <i>et al.</i> , Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program, <u>J. Clin. Oncol.</u> 16: 2825-2833 (1998)			
	MMMMR	McLaughlin <i>et al.</i> , Clinical status and optimal use of rituximab for B-cell lymphomas, <u>Oncology (Huntingt)</u> 12: 1763-1777 (1998)			
	NNNR	Monjour <i>et al.</i> , Lymphomes malins non Hodgkiniens primitifs du système nerveux central, <u>Rev. Neurol. (Paris)</u> 148: 589-600 (1992)			
	OOOR	Morrison <i>et al.</i> , Genetically engineered antibody molecules, <u>Adv. Immunol.</u> 44: 65-92 (1988)			
	PPPR	Morrison <i>et al.</i> , Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains, <u>Proc. Natl. Acad. Sci. USA</u> , 81:6851-6855 (1984)			
	QQQR	Murphy <i>et al.</i> , Antibodies to CD40 prevent Epstein-Barr virus-mediated human B-cell lymphomagenesis in severe combined immune deficient mice given human peripheral blood lymphocytes, <u>Blood</u> 86: 1946-1953 (1995)			
	RRRRR	Nguyen <i>et al.</i> , IDEC-C2B8 anti-CD20 (Rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients, <u>Eur. J. Haematol.</u> 62: 76-82 (1999)			
	SSSR	Offner <i>et al.</i> , T Cell receptor peptide therapy triggers autoregulation of experimental encephalomyelitis, <u>Science</u> 251: 430-432 (1991)			
	TTTTTR	O'Neill <i>et al.</i> , Primary central nervous system non-Hodgkin's lymphoma: Survival advantages with combined initial therapy?, <u>Int'l J. Radiation Oncol. Biol. Phys.</u> 33: 663-673 (1995)			

RECEIVED

TECH CENTER 1000/2900
OCT 01 2003

UUUUR	Orłowski, Hodgkin's disease with leptomeningeal involvement, <u>Cancer</u> 53: 1833-1835 (1984)				
VVVVR	Padlan, A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties, <u>Molec. Immun.</u> 28: 489-498 (1991)				
WWWWR	Padlan, Anatomy of the antibody molecule, <u>Molec. Immun.</u> 31: 169-217 (1994)				
XXXXR	Partridge <i>et al.</i> , Combined use of carboxyl-directed protein pegylation and vector-mediated blood-brain barrier drug delivery system optimizes brain uptake of brain-derived neurotrophic factor following intravenous administration, <u>Pharm. Res.</u> 15: 576-82 (1998)				
YYYYR	Pastan <i>et al.</i> , Intrathecal administration of single-chain immunotoxin, LMB-7 [B3(Fv)-PE38], produces cures of carcinomatous meningitis in a rat model, <u>Proc. Nat'l Acad. Sci. USA</u> 92: 2765-2769 (1995)				
ZZZZR	Perez-Jaffe <i>et al.</i> , Cerebral spinal fluid involvement by Hodgkin's disease diagnosed by CSF cytology and immunocytochemistry, <u>Diagn. Cytopathol.</u> 20:219-223 (1999)				
AAAAAR	Piro <i>et al.</i> , Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma, <u>Ann. Oncol.</u> 10: 655-61 (1999)				
BBBBBR	Press <i>et al.</i> , Monoclonal antibody 1F2 (Anti-CD20) serotherapy of human B cell lymphomas, <u>Blood</u> 69: 584-591 (1987)				
CCCCCR	Ravetch and Kinet, Fc receptors, <u>Annu. Rev. Immunol</u> 9:457-92 (1991)				
DDDDDR	Reni <i>et al.</i> , Therapeutic management of primary central nervous system lymphoma in immunocompetent patients: Results of a critical review of the literature, <u>Ann. Oncol.</u> 8: 227-234 (1997)				
EEEEER	Sandor <i>et al.</i> , Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma, <u>J. Clin. Oncol.</u> 16: 3000-3006 (1998)				
FFFFFR	Schabet <i>et al.</i> , Diagnose und therapie der meningosis neoplastica, <u>Nervenarzt</u> 63: 317-27 (1992)				
GGGGGR	Stamenkovic <i>et al.</i> , A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas, <u>EMBO J.</u> 8: 1403-1410 (1989)				
HHHHHR	Stone <i>et al.</i> , A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma, <u>Blood</u> 88: 1188-97 (1996)				
IIIIIR	Strauchen <i>et al.</i> , Chemotherapy in the management of intraocular lymphoma, <u>Cancer</u> 63: 1918-21 (1989)				
JJJJJR	Tutt <i>et al.</i> , Monoclonal antibody therapy of B cell lymphoma: Signaling activity on tumor cells appears more important than recruitment of effectors, <u>J. Immunol.</u> 161: 3176-3185 (1998)				
KKKKKR	Valentine <i>et al.</i> , B3.9 Structure and function of the B-cell specific 35-37 kDa CD20 protein, In: <u>Leukocyte Typing III</u> (McMichael, Ed., p. 440, Oxford University Press (1987)				
LLLLLR	Valle <i>et al.</i> , Activation of human B lymphocytes through CD40 and interleukin 4, <u>Eur. J. Immunol.</u> 19: 1463-1467 (1989)				
MMMMMR	Valluri <i>et al.</i> , Combination treatment of intraocular lymphoma, <u>Retina</u> 15: 125-9 (1995)				

RECEIVED
OCT 01 2003
TECH CENTER 1600/2900

GN	NNNNNR	van Besien <i>et al.</i> , Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma, <u>Blood</u> 91: 1178-1184 (1998)			
	OOOOOR	Verhoeven <i>et al.</i> , Reshaping human antibodies: Grafting an antilysozyme activity, <u>Science</u> 239: 1534-1536 (1988)			
	PPPPR	Vlasveld <i>et al.</i> , Treatment of low-grade non-Hodgkin's lymphoma with continuous infusion of low-dose recombinant interleukin-2 in combination with the B-cell-specific monoclonal antibody CLB-CD19, <u>Cancer Immunol. Immunother.</u> 40:37-47(1995)			
	QQQQQR	Wang <i>et al.</i> , Induction of bcl-x by CD40 engagement rescues slg-induced apoptosis in murine B cells, <u>J. Immunol.</u> 155: 3722-5 (1995)			
	RRRRRR	White <i>et al.</i> , Anti-CD20 monoclonal antibodies as novel treatments for non-Hodgkin's lymphoma, <u>Pharm. Sci. Technol. Today</u> 2: 95-101 (1999)			
	SSSSSR	Wu <i>et al.</i> , Pharmacokinetics and blood-brain barrier transport of an anti-transferrin receptor monoclonal antibody (OX26) in rats after chronic treatment with the antibody, <u>Drug. Metabol. Dispos.</u> 26: 937-9 (1998)			
	TTTTTR	Youle, Immunotoxins for central nervous system malignancy, <u>Semin. Cancer Biol.</u> 7: 65-70 (1996)			
	UUUUUR				
	VVVVVR				
Examiner		Date Considered: 12/10/03			
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.					

RECEIVED

OCT 01 2003

TECH CENTER 1600/2900

